Odyssey Health completes Phase I SAD trial for concussion drug PRV-002; moving to MAD phase

Odyssey Health, Inc.

Phase I Single Ascending Dosing (SAD) completed with three cohorts; drug PRV-002 safe and well tolerated, no severe adverse events.
Cohort III (8 healthy volunteers) cleared; Safety Review Committee unanimously approved start of Multiple Ascending Dosing (MAD) Cohort I.
Intranasal delivery showed low blood levels of PRV-002, supporting targeted brain delivery hypothesis.
Company planning FDA meeting to present Phase I data; Phase II trial sites and study design under development.
Global concussion treatment market valued at $6.9B (2020), forecast to reach $8.9B by 2027 (Grandview Research).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.